PMID: 40259Jul 1, 1979

A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants

Pharmacology, Biochemistry, and Behavior
S E File, J R Hyde

Abstract

The effects of minor tranquilisers and of stimulant drugs were studied in the Social Interaction test of anxiety in which the illuminance and unfamiliarity of the test arena are manipulated. Acute administration of sodium phenobarbitone (25 mg/kg) was without effect. Acute administration of sodium phenobarbitone (35 mg/kg) and of meprobamate (60 mg/kg) produced sedation: both locomotor activity and social interaction were reduced. On the other hand, amphetamine sulphate (2 mg/kg) and caffeine citrate (20 mg/kg) reduced social interaction, but increased locomotor activity. Chronic administration dissociated the pattern of results produced by sodium phenobarbitone (35 mg/kg) from that produced by flurazepam (0.5 mg/kg). With chronic treatment (5 days) neither drug reduced motor activity, but whereas phenobarbitone increased social interaction regardless of the test illuminance and unfamiliarity, the increase produced by flurazepam was limited to the more stressful test conditions, i.e., when the arena was unfamiliar or brightly lit.

References

Jan 1, 1986·Psychopharmacology·S E File, S Pellow
Jan 1, 1983·Psychopharmacology·J P PascoeB S Kapp
Jan 1, 1984·Psychopharmacology·J M Witkin
Jan 1, 1982·Psychopharmacology·M R Landauer, R L Balster
Jan 1, 1993·Psychopharmacology·R Trullas, P Skolnick
Jan 10, 1989·European Journal of Pharmacology·H A BaldwinS E File
Dec 17, 1991·European Journal of Pharmacology·L NegriF Angelucci
Jun 24, 1993·European Journal of Pharmacology·D A GolombekD P Cardinali
Jul 6, 1993·European Journal of Pharmacology·J D BrioniM W Decker
Oct 1, 1982·Neuropharmacology·S E FileD J Nutt
Dec 1, 1984·Physiology & Behavior·W R Holloway, D H Thor
Jun 1, 1984·Physiology & Behavior·C H Beck, H L Chow
Aug 1, 1980·Pharmacology, Biochemistry, and Behavior·J N Crawley, F K Goodwin
Jul 1, 1981·Pharmacology, Biochemistry, and Behavior·R B MurrayR J Tallarida
Nov 1, 1985·Pharmacology, Biochemistry, and Behavior·S E File, S Pellow
Jul 1, 1985·Pharmacology, Biochemistry, and Behavior·R OettingerK Bättig
Jan 1, 1985·Pharmacology, Biochemistry, and Behavior·S Gerhardt, J M Liebman
May 1, 1985·Pharmacology, Biochemistry, and Behavior·G B Freeman, J B Thurmond
Aug 1, 1988·Pharmacology, Biochemistry, and Behavior·S E FileL J Wilks
Jan 1, 1989·Pharmacology, Biochemistry, and Behavior·H A Baldwin, S E File
Oct 1, 1994·Pharmacology, Biochemistry, and Behavior·S LightowlerI F Tulloch
Aug 1, 1996·Pharmacology, Biochemistry, and Behavior·P C YannielliD P Cardinali
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·S Pellow
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·D Treit
Jan 1, 1986·Neuroscience and Biobehavioral Reviews·R A Shephard
Jan 1, 1990·Pharmacology & Therapeutics·R G Lister
Dec 1, 1979·Journal of Affective Disorders·S E File, J R Hyde

Citations

Jan 1, 1978·British Journal of Pharmacology·S E File, J R Hyde
Jan 1, 1979·Physiology & Behavior·S E File, S V Vellucci
Aug 22, 1973·Psychopharmacologia·L A Syme, G J Syme

Related Concepts

Molecular Motor Activity
Nervousness
Central Nervous System Stimulant [EPC]
Central Nervous System Stimulants
Meprobamate
Anti-Anxiety Effect
Thyramine
Quick-Pep
Harassment, Non-Sexual
Phenobarbital

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.